Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jun 11:12:582768.
doi: 10.3389/fimmu.2021.582768. eCollection 2021.

The Clinical Features of FLAIR-Hyperintense Lesions in Anti-MOG Antibody Associated Cerebral Cortical Encephalitis with Seizures: Case Reports and Literature Review

Affiliations
Case Reports

The Clinical Features of FLAIR-Hyperintense Lesions in Anti-MOG Antibody Associated Cerebral Cortical Encephalitis with Seizures: Case Reports and Literature Review

Yun-Feng Wang et al. Front Immunol. .

Abstract

Background: The presence of fluid attenuated inversion recovery (FLAIR)-hyperintense lesions in anti-myelin oligodendrocyte glycoprotein (MOG) antibody-associated cerebral cortical encephalitis with seizures (FLAMCES) was recently reported. However, the clinical characteristics and outcome of this rare clinico-radiographic syndrome remain unclear.

Methods: The present study reported two new cases. In addition, cases in the literature were systematically reviewed to investigate the clinical symptoms, magnetic resonance imaging (MRI) abnormalities, treatments and prognosis for this rare clinico-radiographic syndrome.

Results: A total of 21 cases were identified during a literature review, with a mean patient age at onset of 26.8 years. The primary clinicopathological characteristics included seizures (100%), headache (71.4%), fever (52.3%) and other cortical symptoms associated with the encephalitis location (61.9%). The common seizure types were focal to bilateral tonic-clonic seizures (28.6%) and unknown-onset tonic-clonic seizures (38.1%). The cortical abnormalities on MRI FLAIR imaging were commonly located in the frontal (58.8%), parietal (70.6%) and temporal (64.7%) lobes. In addition, pleocytosis in the cerebrospinal fluid was reported in the majority of the patients (95.2%). All patients received a treatment regimen of corticosteroids and 9 patients received anti-epileptic drugs. Clinical improvement was achieved in all patients; however, one-third of the patients reported relapse following recovery from cortical encephalitis.

Conclusions: FLAMCES is a rare phenotype of MOG-associated disease. Thus, the wider recognition of this rare syndrome may enable timely diagnosis and the development of suitable treatment regimens.

Keywords: cortical; encephalitis; fluid attenuated inversion recovery; myelin oligodendrocyte glycoprotein; seizure.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
(A) Fluid attenuation inversion recovery (FLAIR) image showed hyperintensity in the cortical region of right frontal and parietal lobes without white matter involvement (Case 1). (B) Diffusion weighted imaging (DWI) showed no obvious signal change in the cortex (Case 1). (C) MRI scan showed the abnormality disappeared at the follow-up scan (Case 1). (D) Hyperintensity in the cortical regions of left parietal lobes in MRI FLAIR images 7 years before this episode (Case 1). (E) DWI showed no obvious signal change in the cortex (Case 1). (F) MRI scan showed the abnormal lesions disappeared at the follow-up scan (Case 1). (G) Hyperintensity in the cortical regions of left frontal and parietal lobes in MRI FLAIR images (Case 2). (H) DWI showed mild hyperintensity in the involved cortical regions (Case 2). (I) Gadolinium enhanced T1-weighted image showed meningeal linear enhancements in the sulci of left brain lobes (Case 2). (J) T2-weighted image showed hyperintensity in the spinal cord from thorax 2 to 9 segments. (Case 2).

Similar articles

Cited by

References

    1. Ramanathan S, Dale RC, Brilot F. Anti-MOG Antibody: The History, Clinical Phenotype, and Pathogenicity of a Serum Biomarker for Demyelination. Autoimmun Rev (2016) 15:307–24. 10.1016/j.autrev.2015.12.004 - DOI - PubMed
    1. Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, et al. . Clinical Spectrum and Prognostic Value of CNS MOG Autoimmunity in Adults: The MOGADOR Study. Neurology (2018) 90:e1858–69. 10.1212/WNL.0000000000005560 - DOI - PubMed
    1. Cobo-Calvo A, Vukusic S, Marignier R. Clinical Spectrum of Central Nervous System Myelin Oligodendrocyte Glycoprotein Autoimmunity in Adults. Curr Opin Neurol (2019) 32:459–66. 10.1097/WCO.0000000000000681 - DOI - PubMed
    1. Yao Y, Xu Y, Ren H, Zhou X, Jin L, Huang Y, et al. . Acute Epileptic Seizures in Myelin Oligodendrocyte Glycoprotein Encephalomyelitis and Neuromyelitis Optica Spectrum Disorder: A Comparative Cohort Study. Mult Scler Relat Disord (2019) 27:281–8. 10.1016/j.msard.2018.11.007 - DOI - PubMed
    1. Ogawa R, Nakashima I, Takahashi T, Kaneko K, Akaishi T, Takai Y, et al. . MOG Antibody-Positive, Benign, Unilateral, Cerebral Cortical Encephalitis With Epilepsy. Neurol Neuroimmunol Neuroinflamm (2017) 4:e322. 10.1212/NXI.0000000000000322 - DOI - PMC - PubMed

Publication types

MeSH terms